Bennett Deboisblanc, MD
Pulmonary Disease · New Orleans, LANPI 1750324463
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,500 of the $9,426 with a category attached, or 79.6%. 15 manufacturers reported payments, led by Cumberland Pharmaceuticals, Inc. at 54.4% of the total. Reporting peaked in 2019 at $4,523 and has fallen 76.8% since, to $1,048 in 2025.
Across 65 payments — averaging $145.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cumberland Pharmaceuticals, Inc.$5K
- Fujifilm Sonosite, Inc.$3K
- United Therapeutics Corporation$527
- Actelion Pharmaceuticals US, Inc.$518
- Boehringer Ingelheim$139
- Mallinckrodt Enterprises LLC$125
- plus $492 from 9 others
Across 9 payments — averaging $49,675 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$433K
- Janssen Research & Development, LLC$14K
What the payments were for
- Consulting fees$7,50080%
- Travel & lodging$1251%
- Food & beverage$1,65318%
- Education$1482%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cumberland Pharmaceuticals, Inc. | 7 | $5,125 |
| Fujifilm Sonosite, Inc. | 1 | $2,500 |
| United Therapeutics Corporation | 17 | $527 |
| Actelion Pharmaceuticals US, Inc. | 13 | $518 |
| Boehringer Ingelheim | 2 | $139 |
| Mallinckrodt Enterprises LLC | 2 | $125 |
| Genentech USA, Inc. | 1 | $125 |
| Gilead | 8 | $118 |
| Johnson & Johnson | 5 | $66 |
| Cook Medical LLC | 2 | $48 |
| AstraZeneca | 2 | $37 |
| Merck | 2 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Bayer | 1 | $26 |
| Portola Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edge/Edge II Ultrasound System$2,500
- Kristalose$2,000
- SANCUSO$2,000
- Vaprisol Dextrose in Plastic Container$2,000
- Caldolor$2,000
- Vibativ$2,000
- UPTRAVI$240
- OPSUMIT$240
- ACTHAR$116
How this compares
$9,426 in reported general payments places this provider in the 70th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 261 | $3,282,053 |
| UptraviSelexipag | 87 | $1,974,698 |
| AdempasRiociguat | 70 | $934,211 |
| WinrevairSotatercept-Csrk | 45 | $690,970 |
| Orenitram ErTreprostinil Diolamine | 53 | $589,975 |
| Ambrisentan | 168 | $588,811 |
| Tyvaso DpiTreprostinil | 13 | $304,535 |
| Tadalafil | 155 | $153,768 |
| LetairisAmbrisentan | 12 | $146,724 |
| AdcircaTadalafil | 23 | $93,799 |
| NucalaMepolizumab | 11 | $39,708 |
| EliquisApixaban | 25 | $15,615 |
| Sildenafil Citrate | 63 | $10,924 |
| Mycophenolate Mofetil | 15 | $2,707 |
| Furosemide | 37 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $518 | $5,256,751348 claims |
| BayerAdempas | $26 | $934,21170 claims |
| MerckWinrevair | $29 | $690,97045 claims |
| GileadLetairis | $118 | $146,72412 claims |
| United Therapeutics CorporationAdcirca | $527 | $93,79923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in New Orleans
- Joseph LaskyNew Orleans$447K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Nicole LapinelNew Orleans$140K
- Courtney ShappleyNew Orleans$66K
- Susan GunnNew Orleans$28K
- David PattenNew Orleans$12K
- Yasin KhanNew Orleans$12K
- Ross KlingsbergNew Orleans$11K
- Nereida ParadaNew Orleans$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.